Methods: The susceptibility of E. coli in France (166 isolates), Germany (133 isolates), Spain (169 isolates), Sweden (137 isolates), and the UK (124 isolates) was determined by disc diffusion according to European Committee on Antimicrobial Susceptibility Testing (EUCAST) breakpoints and methodology. Resistance rates were compared using Fisher's exact test, 2-tailed, with P\0.05 indicating statistical significance.
Results: Since 2000, there has been a significant increase in resistance to cefadroxil in Germany (1% to 12%) and Spain (3% to 8%), to ciprofloxacin in Germany (2% to 21%), Spain (15% to 31%), Sweden (0% to 7%), and the UK (1% to 15%), to trimethoprim in Germany (23% to 37%), Spain (25% to 37%), Sweden (9% to 17%), and the UK (13% to 46%), to mecillinam in Spain (1% to 6.5%), and to nitrofurantoin in the UK (0% to 6%); there was also a significant decrease in resistance to nitrofurantoin in Spain (4% to 0%). Since 2008, there has been a significant increase in resistance to ciprofloxacin in Sweden (3% to 15%) and the UK (1% to 15%), and to trimethoprim (13% to 46%) and nitrofurantoin (0% to 6%) in the UK. 
Conclusion

METHODS
The selection of patients and procedures involved has been reported previously and are summarized only briefly here [3, 4] . [5, 6] . Isolates resistant to the first-generation cephalosporin, cefadroxil, were investigated for production of extended-spectrum beta-lactamase (ESBL) by double disc synergy testing using cefotaxime with and without clavulanic acid and ceftazidime with and without clavulanic acid.
Resistance rates were compared to those amoxicillin-clavulanic acid in the current study was different from that used in the previous studies [7] . Statistical comparison was by Fisher's exact test, 2-tailed, with P\0.05
indicating statistical significance.
All procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation at the respective institutions and with the Helsinki Declaration of 1964, as revised in 2013. No patient identifiers other than sex and age were recorded and, as such, informed consent was not required for inclusion in this study.
RESULTS
Percentage susceptibilities to the agents tested are shown in Table 1 There were only minor differences in methodology between the first two surveys and that reported here. The surveys in 2000 and 2008 involved many centers in each country [3, 4] . In contrast, the latest study was truly multi-center only in France, whereas samples from the other countries came from up to four centers. No upper age limit was imposed on patients in the current study, whereas an upper age limit of 65 years was specified previously. Despite these differences, the three surveys had very important similarities. All involved women with acute uncomplicated UTIs. Urine samples in all three surveys were obtained from women in primary healthcare, with the exception of Germany in the current study, where most of the isolates were from women attending Susceptibility in the current study was determined using EUCAST breakpoints and standardized methodology [5, 6] . The methodology used in the current study was different to that used previously, as it used a different medium and inoculum as specified by EUCAST. However, the zone diameter breakpoints were the same for all antimicrobials with the exception of amoxicillin-clavulanic acid [5] [6] [7] . The most recent guidelines for amoxicillin-clavulanic acid use a fixed concentration of clavulanic acid and apply specifically to urinary isolates [5, 6] . trimethoprim-sulfamethoxazole [8, 9] has been highlighted, and there are similar reports from Germany [10, 11] , along with resistance to cephalosporins [10] . Resistance to quinolones and trimethoprim-sulfamethoxazole in Spain is well documented [12, 13] . Although antimicrobial susceptibility in E. coli isolates in Sweden is generally high, trimethoprim resistance levels have been a cause for concern [14] . Similarly, the high level of trimethoprim resistance in the UK is well documented [15] .
The Antimicrobial Resistance
Epidemiological Survey on Cystitis (ARESC) study in Europe and Brazil, which involved similar patients to those in our study, noted that susceptibility to E. coli of over 90% was found for mecillinam, nitrofurantoin, and fosfomycin only [16] . Although fosfomycin was not tested in our latest study, consistent 
